| Monday, October 8 |
|
3:00 - 7:30 PM
|
Registration
|
Strelitzia
|
|
6:30 - 7:30 PM
|
Welcome Reception
|
Day Restaurant
|
|
7:30 - 7:50 PM
|
Welcome and Orientation
|
Auditorium 2
|
|
*
Margaret A. Liu,
ProTherImmune and Karolinska Institutet
The Unique Scientific and Real-World Challenges of Global Vaccine Development
|
|
|
|
|
|
|
|
|
|
|
|
7:50 - 8:30 PM
|
Keynote Address
|
|
|
N. Regina Rabinovich,
Bill & Melinda Gates Foundation
The Challenges of Translation of Vaccine Research into Impact
|
|
| Tuesday, October 9 |
|
7:00 - 8:00 AM
|
Breakfast
|
Day Restaurant
|
|
8:00 - 11:30 AM
|
Population Differences in Immune Responses to Vaccines and Implications for Childhood and Pandemic Diseases
|
Auditorium 2
|
|
|
|
|
*
Margaret A. Liu,
ProTherImmune and Karolinska Institutet
|
|
|
*
Gustav Nossal,
University of Melbourne
|
|
|
|
|
|
*
Paul-Henri Lambert,
University of Geneva
|
|
|
Myron M. Levine,
University of Maryland School of Medicine
Differences in Immune Responses in Different Populations
|
|
|
Hazel M. Dockrell,
London School Hygiene & Tropical Medicine
BCG Vaccination Induces Different Immune Responses in Malawian and UK Vaccinees
|
|
|
Willem A. Hanekom,
University of Cape Town
BCG-Induced Immune Correlates of Protection Against Tuberculosis
|
|
|
Anne E. Goldfeld,
Harvard Medical School
HIV/TB Host-Pathogen Interactions
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Day Restaurant
|
|
11:30 AM - 12:00 PM
|
Poster Setup
|
Day Restaurant
|
|
12:00 - 2:00 PM
|
Luncheon with Grand Challenges in Global Health Meeting
|
Ballroom
|
|
Harold E. Varmus,
Memorial Sloan Kettering Cancer Center
|
|
|
Bishop Desmond Tutu,
Former Archbishop of Cape Town
|
|
|
Graça Machel,
|
|
|
Tadataka Yamada,
Bill & Melinda Gates Foundation
|
|
|
2:30 - 4:30 PM
|
Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria
|
Auditorium 2
|
|
*
Michal Fried,
Seattle Biomedical Research Institute
|
|
|
|
|
|
*
Stefan H.I. Kappe,
Seattle Biomedical Research Institute
|
|
|
|
|
|
Dominic Kwiatkowski,
Wellcome Trust Centre for Human Genetics
Learning from the Human Genome How Protective Immunity Against Malaria Works
|
|
|
Patrick E. Duffy,
National Institute of Allergy and Infectious Diseases
Protective Immunity Against Severe Malaria in Young Children
|
|
|
|
|
|
Adrian V.S. Hill,
Jenner Institute, Oxford University
Vectored Vaccines for Malaria
|
|
|
Salim Abdulla,
Ifakara Health Research and Development Center
Malaria Vaccine Clinical Trials in Africa
|
|
|
|
|
|
2:30 - 4:30 PM
|
Workshop 2A on Vaccine Technologies: Stability of Vaccines
|
Roof Terrace Room
|
|
*
Marie-Paule Kieny,
Health Technology and Pharmaceuticals, World Health Organization
|
|
|
Colin R. Gardner,
TransForm Pharmaceuticals, Inc.
Increasing Vaccine Stability through Novel Technology
|
|
|
|
|
|
Claire M. Coeshott,
GlobeImmune, Inc.
Thermostable Vaccines with Improved Stability at Non-Refrigerated Temperatures
|
|
|
|
|
|
|
|
|
Yoshikazu Yuki,
Institute of Medical Science
Development of Needle- and Cold-Chain-Free Vaccine: Rice-Based Oral Vaccine
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Day Restaurant
|
|
5:00 - 7:30 PM
|
Effector vs. Memory Responses
|
Auditorium 2
|
|
*
Margaret A. Liu,
ProTherImmune and Karolinska Institutet
|
|
|
*
Carolyn Williamson,
University of Cape Town
|
|
|
|
|
|
Rafi Ahmed,
Emory University School of Medicine
Manipulating Regulatory T Cell in the Development of Vaccines or Translating Innate Immunity into Immunologic Memory: Implications for Vaccine Development
|
|
|
Rudolf A. Manz,
Deutsches Rheuma-Forschungszentrum
Plasma Cell Niches: Molecular Determinants of Long-Lived Plasma Cells
|
|
|
Ken Smith,
Cambridge Institute for Medical Research
The Inhibitory Fc Receptor FcgammaRIIb, Immune Responses, Autoimmunity and Malaria
|
|
|
George M. Shaw,
University of Alabama at Birmingham
Identification of the Transmitted HIV-1 Envelope and Its Evolution in Acute and Early Human Infection
|
|
|
7:30 - 8:30 PM
|
Social Hour w/ Lite Bites
|
Day Restaurant
|
|
8:00 - 10:00 PM
|
Poster Session 1
|
Day Restaurant
|
| Wednesday, October 10 |
|
7:00 - 8:00 AM
|
Breakfast
|
Day Restaurant
|
|
8:00 - 11:30 AM
|
Innate and Adaptive Immune Responses/Adjuvants
|
Auditorium 2
|
|
*
Marie-Paule Kieny,
Health Technology and Pharmaceuticals, World Health Organization
|
|
|
*
Souleymane Mboup,
Universite Cheikh Anta DIOP
|
|
|
Paul-Henri Lambert,
University of Geneva
Towards Effective and Safe Vaccines: Assessing the Risk-Benefit Ratio of Activating Innate Immunity
|
|
|
|
|
|
Alan Aderem,
Institute for Systems Biology
A Systems Approach to Vaccine Development
|
|
|
Eyal Raz,
University of California, San Diego
Irradiated Pathogens to Activate Dendritic Cells via TLRs for the Induction of T Cell Responses
|
|
|
David C. Jackson,
University of Melbourne
The Use of Simple Synthetic Lipid Structures for Targeting Different Vaccine Cargos to Dendritic Cells
|
|
|
Peter Andersen,
Statens Serum Institut
TB Vaccine - Pre/Post Exposure
|
|
|
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Day Restaurant
|
|
11:00 AM - 12:00 PM
|
Poster Setup
|
Day Restaurant
|
|
11:30 - 12:30 AM
|
Lunch
|
Day Restaurant
|
|
12:30 - 2:30 PM
|
Poster Session 2
|
Day Restaurant
|
|
2:30 - 4:30 PM
|
Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines
|
Auditorium 2
|
|
*
Martin Ota,
Medical Research Council
|
|
|
*
Jerald C. Sadoff,
Aeras Global TB Vaccine Foundation
|
|
|
Thomas H.M. Ottenhoff,
Leiden University Medical Center
Results from a Safety and Immunogenicity Clinical Trial with an Adjuvanted Ag85/ESAT6 Subunit Vaccine against Tuberculosis
|
|
|
Helen McShane,
University of Oxford
MVA85A - An Update on Clinical Trials
|
|
|
Greg D. Hussey,
University of Cape Town
BCG and Clinical Trails
|
|
|
Leander Grode,
Vakzine Projekt Management
Developing a TB Vaccine for Human Use
|
|
|
Francois Spertini,
Centre Hospitalier Universitaire Vaudois
Safety and Immunogenicity of the Mtb72F/AS02A Tuberculosis Vaccine
|
|
|
|
|
|
Megan Murray,
Harvard School of Public Health
Modeling of Clinical TB
|
|
|
2:30 - 4:30 PM
|
Workshop 2B on Vaccine Technologies: Needle Free Delivery, Aerosol Delivery and Nanoparticles
|
Roof Terrace Room
|
|
*
Sujit Kuman Bhattacharya,
National Institute of Cholera and Enteric Diseases
|
|
|
Ana Maria Henao-Restrepo,
World Health Organization
Development of a Measles Aerosol Vaccine
|
|
|
|
|
|
David A. Edwards,
Harvard University
Dry Powder Nanoparticle Inhaled Aerosols for Needle-Free Vaccination
|
|
|
Robert E. Sievers,
University of Colorado
Needle-Free Delivery of Stable, Respirable Dry Powder Measles Vaccine Formulations
|
|
|
James R. Baker Jr.,
University of Michigan
Naoemulsions as Adjuvants for Nasal-Spray Vaccines
|
|
|
David D. Lo,
University of California, Riverside
Development of a Targeted Mucosal Vaccine Delivery Technology
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Day Restaurant
|
|
5:00 - 7:30 PM
|
Neonatal and Infant Immunity
|
Auditorium 2
|
|
|
|
|
*
Claire-Anne Siegrist,
University of Geneva
Challenges and Perspectives for Optimal Early Life Vaccine Responses
|
|
|
Lorne A. Babiuk,
University of Alberta
Linking Innate and Specific Immunity to Develop Single-Dose Vaccines for Neonates
|
|
|
Victoria Jane Philbin,
Children's Hospital
Distinct Function of Toll-Like Receptors (TLRs) in Human Neonatal Antigen-Presenting Cells: Unique Potential of TLR8 Agonists as Neonatal Vaccine Adjuvents
|
|
|
Martha Sedegah,
Naval Medical Research Center
Immunological Responses of Neonates and Infants to DNA-Based Vaccines
|
|
|
|
|
|
Mustafa Akkoyunlu,
U.S. Food And Drug Administration
Differences in Adult and Neonatal BAFF/APRIL System: Implications for Polysaccharide Vaccines
|
|
| Thursday, October 11 |
|
7:00 - 8:00 AM
|
Breakfast
|
Day Restaurant
|
|
8:00 - 11:15 AM
|
Vaccines Impacting on Microbial Ecology
|
Auditorium 2
|
|
*
Luis Jodar,
International Vaccine Institute
|
|
|
*
Stefan H.E. Kaufmann,
Max Planck Institute for Infection Biology-Berlin
|
|
|
Richard Adebayo Adegbola,
Medical Research Council
Haemophilus influnzae type b (Hib) Conjugate Vaccine: Clinical Trials and Implementation of an Effective Routine Hib Immunization Programme in The Gambia
|
|
|
Helena Käyhty,
National Public Health Institute
The Use of Nasopharyngeal Carriage as an End Point for Efficacy Trials and Registration and Use of New Pneumococcal Vaccine Formulations
|
|
|
Shabir Madhi,
University of the Witwatersrand
Pneumococcal Conjugate Vaccine in Developing Countries: Potential for Addressing the Ignored Epidemic
|
|
|
Jonathan Carapetis,
Menzies School of Health Research
Global Burden of Group A Streptococcal Disease, and Progress in Vaccine Development
|
|
|
John D. Clemens,
International Vaccine Institute
New Approaches to the Assessment of Vaccine Herd Immunity and Herd Protection
|
|
|
|
|
|
11:15 - 11:30 AM
|
Special Announcement
Dr. Jose Esparza, Senior Advisor on HIV Vaccines for the Bill & Melinda Gates Foundation, will announce an important new development in the growth of the Global HIV Vaccine Enterprise, an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Originally proposed in 2003, the purpose of the Enterprise is to build consensus in the HIV vaccine field on scientific priorities, mobilize new resources to implement these priorities, and facilitate the rapid sharing of information that can advance the field as a whole. To date, the Enterprise has mobilized more than $750 million in support of its scientific plan.
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Day Restaurant
|
|
11:30 AM - 12:00 PM
|
Poster Setup
|
Day Restaurant
|
|
11:30 AM - 12:30 PM
|
Lunch
|
Day Restaurant
|
|
12:30 - 2:30 PM
|
Poster Session 3
|
Day Restaurant
|
|
2:30 - 4:30 PM
|
Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines
|
Auditorium 2
|
|
*
Glenda Gray,
University of the Witwatersrand
|
|
|
|
|
|
Blake Ball,
University of Manitoba
Comprehensive Studies of Mechanisms of HIV Resistance in Highly Exposed Uninfected Women
|
|
|
|
|
|
George K. Lewis,
University of Maryland, Institute of Human Virology
Targeting Co-receptor Steps for Protective Immunity Against HIV-1
|
|
|
Hongkui Deng,
Peking University
Development of Novel Mouse Models for HIV and HCV Infection
|
|
|
Rudi Balling,
Centre for Systems Biology Luxembourg, University of Luxembourg
Novel Mouse Models for Testing HIV and HCV Vaccines
|
|
|
Michael Ott,
Hannover Medical School
Novel Mouse Models for Testing HIV and HCV Vaccines
|
|
|
2:30 - 4:30 PM
|
Workshop 1D: Enteric Pathogens
|
Roof Terrace Room
|
|
*
John D. Clemens,
International Vaccine Institute
|
|
|
Firdausi Qadri,
International Centre for Diarrhoeal Disease Research, Bangladesh
Mucosal Immunity to Common Enteric Pathogens and Relevance to Vaccine Development
|
|
|
Sujit Kuman Bhattacharya,
National Institute of Cholera and Enteric Diseases
Field Trial of Enteric Vaccines in Kolkata
|
|
|
Gregory M. Glenn,
IOMAI Corporation
Transcutaneous Immunization with LT: Development of a Needle-Free Vaccine Patch
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Day Restaurant
|
|
5:00 - 7:30 PM
|
Mucosal and Dermal Vaccines and Immunity
|
Auditorium 2
|
|
|
|
|
*
Gustav Nossal,
University of Melbourne
|
|
|
Charles J. Arntzen,
Biodesign Institute, Arizona State University
Progress in Plant-Made Vaccines
|
|
|
Robin Shattock,
St. Georges, University of London
Novel Antigen Design and Delivery for Mucosal Protection Against HIV-1 Infection
|
|
|
Roy Curtiss III,
Arizona State University
A Live Recombinant Attenuated Salmonella Anti-Pneumococcal Vaccine for Newborns
|
|
|
|
|
|
Behazine Combadière,
INSERM U945
Short Talk: Follicular Targeting: From Skin Explant to Transcutaneous Vaccination in Humans
|
|
| Friday, October 12 |
|
7:00 - 8:00 AM
|
Breakfast
|
Day Restaurant
|
|
8:00 - 11:45 AM
|
Correlates of Immunity in Pre-Clinical Models and Clinical Studies
|
Auditorium 2
|
|
*
Glenda Gray,
University of the Witwatersrand
|
|
|
Stefan H.E. Kaufmann,
Max Planck Institute for Infection Biology-Berlin
Towards Characterization of Protective Immunity against TB
|
|
|
|
|
|
Markus G. Manz,
Institute for Research in Biomedicine
A Mouse Model to Evaluate Live Attenuated Vaccine Candidates
|
|
|
|
|
|
Britta E. Wahren,
Karolinska Institute
Progress of the HIV Vaccine Phase I/II Immunogenicity Study (HIVIS Project) in Dar es Salaam, Tanzania: HIV-1 DNA Plasmid Prime and MVA Boost
|
|
|
|
|
|
Sarah L. Rowland-Jones,
MRC Human Immunology Unit
Long-Term Non-Progression with HIV Infection: Lessons from HIV-2
|
|
|
Carolyn Williamson,
University of Cape Town
Multigene Human Immunodeficiency Virus Type 1 Subtype C DNA and Modified Vaccinia Ankara (MVA) Vaccine
|
|
|
|
|
|
*
Gary J. Nabel,
National Institutes of Health
Development and Evaluation of a T-Cell Based Multi-Clade AIDS Vaccine
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Day Restaurant
|
|
2:30 - 4:30 PM
|
Workshop 3: Issues for Introducing Vaccines to Developing Countries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing
|
Auditorium 2
|
|
*
José G. Esparza,
Bill & Melinda Gates Foundation
|
|
|
Bernard Fourie,
Medicine in Need
Challenges to Vaccine Access in High-Burden Settings
|
|
|
Duncan Steele,
World Health Organization
Delivering Rotavirus Vaccines to Impact the Millennium Development Goals
|
|
|
Jean Stephenne,
GlaxoSmithKline Biologicals
GSK Issues for Global Vaccine Manufacturers
|
|
|
Luis Jodar,
International Vaccine Institute
Translational Research to Assist Policy Decisions about Introducing New Vaccines into Developing Countries
|
|
|
Carl E. Frasch,
Frasch Biologics Consulting
Strategies for Production of Pneumococcal Conjugate Vaccines in and for Developing Countries
|
|
|
|
|
|
2:30 - 4:30 PM
|
Workshop 2C on Vaccine Technologies and Other Novel Technologies: Mucosal and Dermal Vaccines
|
Roof Terrace Room
|
|
|
|
|
*
Britta E. Wahren,
Karolinska Institute
Novel Delivery Devices and Approaches for Immunization
|
|
|
*
Rachel Chikwamba,
Council for Scientific and Industrial Research (CSIR)
Plant Derived Vaccines for Mucosal Delivery
|
|
|
Edward P. Rybicki,
University of Cape Town
Plant-Produced Vaccines: Promise and Reality
|
|
|
|
|
|
Philippe E. Laurent,
Becton Dickinson
Evaluation of the Clinical Performance of BD™ Microinjection System for Intradermal Vaccine Delivery
|
|
|
|
|
|
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Day Restaurant
|
|
5:00 - 6:30 PM
|
Novel Approaches to Immunity
|
Auditorium 2
|
|
*
Margaret A. Liu,
ProTherImmune and Karolinska Institutet
|
|
|
*
Gustav Nossal,
University of Melbourne
|
|
|
|
|
|
Reinhard Kurth,
Robert Koch Institute
Novel Approaches to Flu Vaccine Development
|
|
|
Abraham L. Sonenshein,
Tufts University, School of Medicine
Bacterial Spores as Heat-Stable Vaccine Delivery Systems
|
|
|
Lennart Hammarström,
Karolinska Institute
Passive Immunity via Orally-Administered lactobacilli
|
|
|
6:30 - 7:30 PM
|
Concluding Keynote Address
|
Auditorium 2
|
|
|
|
|
Anna-Lise Williamson,
University of Cape Town
Vaccine Development: An Essential Part of Health Security in Africa
|
|
|
7:30 - 8:30 PM
|
Social Hour w/ Lite Bites
|
Day Restaurant
|
|
8:00 - 11:00 PM
|
Entertainment
|
Day Restaurant
|
| Saturday, October 13 |
|
|
Departure
|
|
